GEO 001: What is the dose-response curve between allopurinol and its effects on endothelial function in heart failure patients?

Completed

• Conditions: Chronic Heart Failure; Circulatory System

• Registration Number: ISRCTN44536106
• Lead Sponsor: niversity of Dundee (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01-27
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Three-month period free of hospitalisations prior to screening

2. Ability to give written informed consent to participate in the study

3. Diagnosis of mild to moderate chronic heart failure

Exclusion Criteria

1. History of drug sensitivity or allergy to allopurinol or vitamin C

2. Current treatment with allopurinol , theophylline or cytotoxic drugs (including azothiaprine or mercaptopurine)

3. History of acute gout

4. Evidence of significant disease that could impair absorption, metabolism or excretion of orally administered medication i.e.

a. Renal disease (serum creatinine >160 umol/l)

b. Clinically significant hepatic disease (either by lab work, i.e. alanine aminotranferease (ALT) and aspartate aminotransferase (AST) (ALT/AST > 3 times upper limit of normal, or by clinical assessment)

5. Any condition with sufficient severity to impair co-operation in the study

6. History of chronic alcoholism / intravenous drug abuse

7. Use of another investigational drug within three months of entry into the study or within five half-lives of the investigational drug (the longer time period applying)

8. Pregnancy, breast feeding or being of childbearing age and not taking oral contraceptives

Study & Design

• Study Type: Interventional
• Study Design: Not specified